🔥🐔 BizChicken 🐔🔥

Companies Similar to Allogene Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Engineered T Cell Therapeutics

CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.

Tags: T cell therapeutics, biotechnology, cancer treatment, hematologic malignancies, immunotherapy

Symbol: CERO

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Christopher B. Ehrlich M.B.A.

Sector: Healthcare

Employees: 8

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650-407-2376

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

AlloVir, Inc.

AlloVir, Inc. logo
Market Cap: Low
Employees: Lowest

posoleucel

Allovir, Inc. is a clinical-stage cell therapy company focused on the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat viral-associated diseases. It was founded in 2013 and is based in Waltham, Massachusetts.

Tags: VST therapies, biotechnology, cell therapy, clinical-stage, viral diseases

Symbol: ALVR

Recent Price: $0.45

Industry: Biotechnology

CEO: Dr. Diana M. Brainard M.D.

Sector: Healthcare

Employees: 8

Address: 1100 Winter Street, Waltham, MA 02451

Phone: 617 433 2605

Last updated: 2024-12-31

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. logo
Market Cap: Low
Employees: Low

ALX148

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.

Tags: CD47, cancer therapy, clinical trials, collaboration, immuno-oncology, solid tumors

Symbol: ALXO

Recent Price: $1.66

Industry: Biotechnology

CEO: Mr. Jason W. Lettmann

Sector: Healthcare

Employees: 81

Address: 323 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 466 7125

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Century Therapeutics, Inc.

Century Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

CNTY-101

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Tags: CAR-i NK, CAR-i T, allogeneic, biotechnology, cell therapy, hematological malignancies, iPSC, solid tumors

Symbol: IPSC

Recent Price: $1.00

Industry: Biotechnology

CEO: Mr. Brent Pfeiffenberger M.B.A., Pharm.D.

Sector: Healthcare

Employees: 152

Address: 3675 Market Street, Philadelphia, PA 19104

Phone: 267 817 5790

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Adoptive TCR Engineered T-cell Therapies

Alaunos Therapeutics is a clinical-stage company focused on developing cell therapies for cancer treatment, utilizing TCR engineered T-cell therapies in clinical trials for various cancers.

Tags: TCR Library, biotechnology, cancer treatment, cell therapy, clinical trials, oncology

Symbol: TCRT

Recent Price: $2.17

Industry: Biotechnology

CEO: Mr. Dale Curtis Hogue Jr.

Sector: Healthcare

Employees: 1

Address: 8030 El Rio Street, Houston, TX 77054

Phone: 346 355 4099

Last updated: 2024-12-31

TScan Therapeutics, Inc.

TScan Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

T cell receptor-engineered T cell therapies

TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.

Tags: Novartis collaboration, SARS-CoV-2, T cell therapies, biopharmaceutical, cancer treatment, hematologic malignancies, infectious diseases, solid tumors

Symbol: TCRX

Recent Price: $3.00

Industry: Biotechnology

CEO: Dr. Gavin MacBeath Ph.D.

Sector: Healthcare

Employees: 175

Address: 830 Winter Street, Waltham, MA 02451

Phone: 857 399 9500

Leadership

  • Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
  • Katina Dorton, J.D., M.B.A., CFO of Nodthera
  • Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
  • Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
  • Gavin MacBeath, Ph.D., CEO of TSCAN
  • Garry Nicholson, Former President of Pfizer Oncology
  • R. Keith Woods, Former Chief Operating Officer of argenx

Last updated: 2024-12-31

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

XCART

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.

Tags: CAR T, biopharmaceutical, biotechnology, drug delivery, oncology, therapeutics

Symbol: XBIO

Recent Price: $4.05

Industry: Biotechnology

CEO: Mr. James F. Parslow

Sector: Healthcare

Employees: 4

Address: 40 Speen Street, Framingham, MA 01701

Phone: 781 778 7720

Leadership

  • James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
  • Scott N. Cullison, Business Development
  • Reid P. Bissonnette, Ph.D., Translational Research and Development
  • Cory C. Kauffman, Ph.D., Chief Technology Officer
  • Adam Logal, Chairman
  • Grigory G. Borisenko, Ph.D., Non-Executive Director
  • James Eric Callaway, Ph.D., Non-Executive Director
  • Firdaus Jal Dastoor, FCS, Non-Executive Director
  • Dmitry Genkin, MD, Non-Executive Director
  • Roger Kornberg, Ph.D., Non-Executive Director
  • Moshe Mizrahy, Non-Executive Director
  • Dr. Alexey Vinogradov, Non-Executive Director

Last updated: 2024-12-31

Arcus Biosciences, Inc.

Arcus Biosciences, Inc. logo
Market Cap: High
Employees: Medium

Cancer Therapies

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing cancer therapies, with a pipeline including products like Etrumadenant, Zimberelimab, and Domvanalimab among others.

Tags: biopharmaceutical, cancer therapies, clinical trials, oncology

Symbol: RCUS

Recent Price: $14.91

Industry: Biotechnology

CEO: Dr. Terry J. Rosen Ph.D.

Sector: Healthcare

Employees: 577

Address: 3928 Point Eden Way, Hayward, CA 94545

Phone: 510 694 6200

Last updated: 2024-12-31